Source:http://linkedlifedata.com/resource/pubmed/id/17927299
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
2007-10-11
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
1172-7047
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
21
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
957-65
|
pubmed:meshHeading |
pubmed-meshheading:17927299-Administration, Cutaneous,
pubmed-meshheading:17927299-Alzheimer Disease,
pubmed-meshheading:17927299-Cholinesterase Inhibitors,
pubmed-meshheading:17927299-Clinical Trials as Topic,
pubmed-meshheading:17927299-Humans,
pubmed-meshheading:17927299-Phenylcarbamates,
pubmed-meshheading:17927299-Treatment Outcome
|
pubmed:year |
2007
|
pubmed:articleTitle |
Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type.
|
pubmed:affiliation |
Wolters Kluwer Health 1 Adis, Auckland, New Zealand. demail@adis.co.nz
|
pubmed:publicationType |
Journal Article,
Review
|